ESR1 and breast carcinoma: SERMs (Tamoxifen, Toremifene and Fulvestrant), perform their action by binding to the oestrogen receptor [22]; in breast tissue, Tamoxifen acts as an ER antagonist, inhibiting the activity of oestrogens and, for this reason, it is commonly used as to treat breast cancer.